hVIVO plc (LON:HVO - Get Free Report)'s stock price shot up 10% on Monday . The company traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). 7,804,669 shares changed hands during trading, an increase of 164% from the average session volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Stock Performance
The firm has a market cap of £144.58 million, a P/E ratio of 708.33 and a beta of 0.97. The company's 50-day moving average is GBX 20.25 and its two-hundred day moving average is GBX 25.68. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
